Press release
Emesis Market to Reach USD 10.4 Billion by 2034
Emesis
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71135
The growing burden of cancer therapies, gastrointestinal disorders, and post-surgical interventions is fueling demand for antiemetic drugs and therapies. Increasing research into next-generation antiemetics, rising healthcare expenditure, and improved access to treatment in emerging economies are shaping the future of the emesis market.
Market Overview
• Market Size (2024): USD 5.9 billion
• Forecast (2034): USD 10.4 billion
• CAGR (2025-2034): 5.7%
The emesis market is expanding steadily as patient populations with CINV, post-operative nausea and vomiting (PONV), and gastrointestinal disorders continue to rise globally. Pharmaceutical innovation, particularly in serotonin receptor antagonists and neurokinin-1 (NK1) receptor antagonists, remains central to growth.
Key Highlights:
• Increasing prevalence of cancer driving demand for CINV management.
• Growing adoption of combination therapies (5-HT3 antagonists + NK1 antagonists).
• High focus on patient quality of life and treatment adherence.
• Expanding distribution networks improving access in emerging markets.
• Side effects and generic competition remain key challenges.
Segmentation Analysis
By Product:
• 5-HT3 Receptor Antagonists (Ondansetron, Granisetron, Palonosetron)
• NK1 Receptor Antagonists (Aprepitant, Fosaprepitant, Netupitant)
• Dopamine Antagonists (Metoclopramide, Prochlorperazine)
• Antihistamines & Anticholinergics
• Cannabinoids (Dronabinol, Nabilone)
• Combination Therapies
By Platform:
• Small Molecules
• Biologics
• Combination Therapies
By Technology:
• Oral Drug Formulations
• Injectable Therapies
• Transdermal Patches
• Emerging Delivery Platforms
By End Use:
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Retail Pharmacies
By Application:
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Post-Operative Nausea and Vomiting (PONV)
• Pregnancy-Induced Nausea (Hyperemesis Gravidarum)
• Gastroenteritis & Motion Sickness
• Others (neurological disorders, medication-induced nausea)
Segmentation Summary:
CINV represents the largest application segment, with NK1 receptor antagonists and combination therapies leading the therapeutic landscape. Hospitals dominate end-use due to their role in cancer care and surgical recovery, while retail pharmacies contribute significantly to motion sickness and pregnancy-related nausea management.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71135/emesis-market
Regional Analysis
North America
• Largest market with ~39% share in 2024.
• Strong presence of leading pharmaceutical players.
• High demand for advanced CINV therapies in oncology centers.
Europe
• Accounts for ~29% market share.
• Rising adoption of biologics and combination antiemetics.
• Germany, UK, and France lead in innovation and reimbursement coverage.
Asia-Pacific
• Fastest-growing region with a CAGR of ~7%.
• Expanding oncology patient base in China, India, and Japan.
• Increasing healthcare access and affordability driving adoption.
Middle East & Africa
• Smaller market share, limited by awareness and access.
• Gradual improvements in hospital infrastructure support steady growth.
Latin America
• Brazil and Mexico emerging as key growth contributors.
• Growing oncology programs and rising awareness about antiemetic therapies.
Regional Summary:
North America and Europe dominate the current market due to strong oncology treatment frameworks and reimbursement policies, while Asia-Pacific will show the highest growth momentum through 2034, driven by cancer incidence and improved healthcare infrastructure.
Market Dynamics
Key Growth Drivers:
• Increasing incidence of cancer requiring chemotherapy.
• Growing number of surgical procedures worldwide.
• Rising demand for pregnancy-related nausea management.
• Expanding R&D investments in novel antiemetics.
• Availability of generics improving affordability in emerging economies.
Key Challenges:
• Side effects such as constipation and headaches from long-term antiemetic use.
• Patent expirations and generic erosion reducing profit margins.
• Regional disparities in availability and affordability of advanced therapies.
Latest Trends:
• Use of cannabinoids for refractory CINV cases.
• AI-driven drug discovery platforms targeting new antiemetic pathways.
• Development of sustained-release formulations and patches.
• Strategic collaborations between oncology centers and pharma firms.
• Personalized medicine approaches for better patient outcomes.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71135
Competitor Analysis
Major Players in the Market:
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company
• Helsinn Healthcare SA
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
Competitive Summary:
The emesis market is moderately consolidated, with leading pharmaceutical players competing through product launches, patent strategies, and distribution expansion. Companies such as Roche and Merck dominate CINV management, while Takeda and Helsinn are strong in NK1 receptor antagonists. Generics manufacturers like Teva and Dr. Reddy's are expanding affordability, particularly in Asia-Pacific and Latin America.
Conclusion
The Emesis Market, valued at USD 5.9 billion in 2024, is projected to reach USD 10.4 billion by 2034, growing at a CAGR of 5.7%. Rising cancer prevalence, growing surgical volumes, and broader awareness of antiemetic therapies will drive sustained demand.
Key Takeaways:
• CINV remains the largest application area, driving growth in NK1 and 5-HT3 antagonists.
• North America and Europe lead the market, but Asia-Pacific will grow fastest.
• Combination therapies and novel delivery platforms are shaping future demand.
• Competitive intensity is increasing as generics gain ground alongside biologic innovation.
The next decade will transform emesis management, with innovation in biologics, cannabinoids, and precision medicine driving improved patient quality of life and adherence to critical treatments like chemotherapy.
This report is also available in the following languages : Japanese (嘔吐市場), Korean (구토 시장), Chinese (呕吐市场), French (Marché des vomissements), German (Emesis-Markt), and Italian (Mercato dell'emesi), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71135/emesis-market#request-a-sample
Our More Reports:
Systemic Lupus Erythematosus Market
https://exactitudeconsultancy.com/reports/71329/systemic-lupus-erythematosus-market
Systemic Sclerosis-associated Interstitial Lung Disease Market
https://exactitudeconsultancy.com/reports/71331/systemic-sclerosis-associated-interstitial-lung-disease-market
Arthralgia Market
https://exactitudeconsultancy.com/reports/71333/arthralgia-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emesis Market to Reach USD 10.4 Billion by 2034 here
News-ID: 4159671 • Views: …
More Releases from Exactitude Consultancy
Psoriasis Market Emerging Trends and Growth Prospects 2034
Introduction
Psoriasis is a chronic, immune-mediated skin disease affecting more than 125 million people worldwide. Characterized by red, scaly plaques, the condition significantly impacts quality of life and is often associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and depression.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71327
Management has historically relied on topical agents and systemic therapies, but the introduction of biologics and targeted oral small molecules has revolutionized…
Myasthenia Gravis Market to Reach USD 2.5 Billion by 2034
Myasthenia gravis (MG) is a rare, chronic autoimmune neuromuscular disorder characterized by muscle weakness, fatigue, and impaired communication between nerves and muscles. It is primarily caused by antibodies targeting acetylcholine receptors (AChR), muscle-specific kinase (MuSK), or related proteins. Without treatment, MG can cause severe disability and life-threatening respiratory complications.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71325
Historically, therapy centered on cholinesterase inhibitors, corticosteroids, and immunosuppressants, but the treatment landscape…
Leukocyte Adhesion Deficiency Market Projected to Reach USD 1.2 Billion by 2034
Leukocyte adhesion deficiency (LAD) is a rare primary immunodeficiency disorder caused by genetic defects that impair the ability of white blood cells (leukocytes) to migrate to infection sites. This results in severe recurrent infections, impaired wound healing, and high mortality in early life if untreated.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71323
Traditionally managed with antibiotics, antifungals, and hematopoietic stem cell transplantation (HSCT), the treatment paradigm is now shifting…
Systemic Lupus Erythematosus (SLE) Market Detailed Industry Report Analysis 2025 …
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where the immune system attacks multiple organ systems, including skin, joints, kidneys, and blood vessels. It is often unpredictable, with flare-ups and remissions that complicate management. Symptoms range from fatigue and skin rashes to life-threatening organ damage.
While conventional treatments such as corticosteroids, antimalarials, and immunosuppressants remain central, recent years have seen significant advances with biologics, targeted therapies, and precision medicine approaches.…
More Releases for CINV
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vo …
The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV)…
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 202 …
How Are the key drivers contributing to the expansion of the chemotherapy-induced nausea and vomiting (cinv) market?
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would…
Advancements and Trends in the Global Chemotherapy-induced Nausea and Vomiting ( …
Introduction:
The realm of cancer treatment is a dynamic arena where advancements continuously unfold. Among the multitude of challenges that cancer patients face, chemotherapy-induced nausea and vomiting (CINV) is a formidable adversary. In this article, we delve into the intricate landscape of the CINV market, exploring its evolution, current state, and future prospects.
Understanding CINV:
CINV, an acronym that echoes the discomfort experienced by countless individuals, stands for chemotherapy-induced nausea and vomiting. This…
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market Research Re …
This report studies Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
GlaxoSmithKline Plc
Helsinn Group
Heron Therapeutics
Merck & Co Inc
Tesaro
...
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of…
